<var id="ndj7z"><video id="ndj7z"><thead id="ndj7z"></thead></video></var>
<menuitem id="ndj7z"><strike id="ndj7z"><thead id="ndj7z"></thead></strike></menuitem>
<var id="ndj7z"></var>
<var id="ndj7z"><video id="ndj7z"></video></var>
<cite id="ndj7z"></cite>
<var id="ndj7z"></var>
<var id="ndj7z"></var>
<cite id="ndj7z"><strike id="ndj7z"><menuitem id="ndj7z"></menuitem></strike></cite> <cite id="ndj7z"><video id="ndj7z"></video></cite>
<cite id="ndj7z"><video id="ndj7z"><menuitem id="ndj7z"></menuitem></video></cite>
<var id="ndj7z"><strike id="ndj7z"></strike></var><var id="ndj7z"></var>
您好,歡迎訪問中山大學腫瘤防治中心官方網站!
內部網 職工郵箱 圖書館 OA系統 醫生門戶 English
院士風采 首席專家 臨床專家 科研學者 客座教授 人才名錄 護理專家
首頁
  • 夏良平

    職務:綜合科副主任
    職稱:腫瘤學博士,主任醫師,博士生導師
    專長:主要從事腫瘤綜合治療;腸癌、肺癌、乳腺癌等常見腫瘤的內科治療(尤其是靶向治療);VIP病人保健和管理。
      夏良平,男,1969年8月9日出生,安徽省懷寧縣人。腫瘤學博士,主任醫師,博士生導師,中山大學腫瘤防治中心綜合科科室副主任。主要從事腫瘤綜合治療;腸癌、肺癌、乳腺癌等常見腫瘤的內科治療(尤其是靶向治療);VIP病人保健和管理。至今發表科研論文146篇,其中第一作者/通訊作者95篇(包括56篇SCI論文),包括J Clin Invest;Nat Commun;Clin Cancer Res;J Immunother Cancer;Mol Ther;JNCCN;Int J Cancer;Aging;J Transl Med;Sci Rep等雜志。主持14項科研基金,包括3項國家自然科學基金。
      另外,承擔全院“靜脈輸液港植入術”,至今有近1000例植入術經驗,并成功舉辦四期“靜脈輸液港植入術和護理技術培訓班”的廣東省繼續教育項目和一屆“海峽兩岸輸液港技術論壇”。

    學習工作經歷:
    1989~1994 安徽醫科大學醫學系
    1994~1996 安徽醫科大學第一附屬醫院外科
    1996~1999 中山大學附屬第一醫院(碩士生)
    1999~2002 中山大學附屬腫瘤醫院(博士生)
    2002~     中山大學附屬腫瘤醫院綜合科

    社會任職
    1.廣東省健康管理學會腫瘤防治專業委員會,主任委員
    2.廣東省健康管理學會干細胞與再生醫學專委會,副主任委員
    3.廣東省抗癌協會靶向與個體化治療專業委員會,常委
    4.廣東省抗癌協會化療專業委員會,委員
      夏良平,男,1969年8月9日出生,安徽省懷寧縣人。腫瘤學博士,主任醫師,博士生導師,中山大學腫瘤防治中心綜合科科室副主任。主要從事腫瘤綜合治療;腸癌、肺癌、乳腺癌等常見腫瘤的內科治療(尤其是靶向治療);VIP病人保健和管理。至今發表科研論文146篇,其中第一作者/通訊作者95篇(包括56篇SCI論文),包括J Clin Invest;Nat Commun;Clin Cancer Res;J Immunother Cancer;Mol Ther;JNCCN;Int J Cancer;Aging;J Transl Med;Sci Rep等雜志。主持14項科研基金,包括3項國家自然科學基金。
      另外,承擔全院“靜脈輸液港植入術”,至今有近1000例植入術經驗,并成功舉辦四期“靜脈輸液港植入術和護理技術培訓班”的廣東省繼續教育項目和一屆“海峽兩岸輸液港技術論壇”。

    學習工作經歷:
    1989~1994 安徽醫科大學醫學系
    1994~1996 安徽醫科大學第一附屬醫院外科
    1996~1999 中山大學附屬第一醫院(碩士生)
    1999~2002 中山大學附屬腫瘤醫院(博士生)
    2002~     中山大學附屬腫瘤醫院綜合科

    科研經歷:
    一.基金
    (一)第一負責人基金
    1.中山大學腫瘤防治中心特支計劃:臨床科學家項目,2019,主持
    2.中山大學腫瘤防治中心308項目:二甲雙胍聯合FOLFIRI二線治療非糖尿病RAS突變型轉移性結直腸癌的多中心、單臂Ⅱ期臨床研究,2019,主持
    3.國家自然科學基金項目(81572409):LDH預測bevacizumab治療轉移性結直腸癌療效的機制及新靶點的探索性研究。(2015)
    4.國家自然科學基金項目(81272641):同步干預2,3-DPG和PKM2在提高Bevacizumab治療腸癌療效中的關鍵作用。(2012)
    5.國家自然科學基金項目(81071872):Cetuximab通過下調SGLT1誘導腸癌細胞自噬性死亡是其抗腫瘤和增敏化療的新機制。(2010)
    6.廣東省自然科學基金(2015A030313010):AMPK/mTOR通路在cetuximab誘發腸癌細胞自噬過程中的作用與意義。(2015年)
    7.廣州市科技計劃項目(1563000305):Adenosine聯合siRNA-PKM2克服bevacizumab的“促癌作用”并提高其殺傷腸癌細胞能力的研究。(2015)
    8.廣東省科技計劃項目(2011B061300069):3-MA阻斷肺癌H460細胞自噬而提高Cetuximab+DDP抗腫瘤效應。(2011)
    9.廣東省科技計劃項目(2008B06060029):siRNA抑制eIF4E后喉癌細胞株Hep2蛋白質表達譜變化的研究。(2008年)
    10.廣東省自然科學基金(9151008901000102):不同p53背景下VX-680聯合Taxol殺傷鼻咽癌細胞的療效差異。(2009年)
    11.廣東省衛生廳項目:乳腺癌中Aurora-A表達與含Taxanes誘導化療方案療效關系的研究。(2008)。
    12.“重大新藥創新”科技重大專項基金:自噬性細胞死亡在Cetuximab聯合Oxaliplatin/Irinotecan方案治療腸癌中的作用。(2008ZX09312-002). 
    13.廣東省衛生廳基金:利用18FDG探測喉癌手術創面中腫瘤殘留狀況的研究。(B2004058)
    14.中山大學腫瘤防治中心基金:利用18FDG探測喉癌手術創面中腫瘤殘留狀況的研究。(303041080562)。

    (二)第二負責人基金
    15.廣東省科技計劃項目(2010B031600317):Cetuximab 下調SGLT1誘導腸癌細胞自噬為增敏Irinotecan的新機制(2010)。
    16.廣東省衛生廳基金(C2011019):結直腸癌患者標準化與個體化治療相結合體系的建立與優化(2012)。
    17.廣東省科技計劃項目(20012137-C30305):喉鱗癌手術切緣eIF4E、P53研究在喉功能保全性治療中的應用。(2001)。

    (三)第三負責人基金
    18. 高等學校博士學科點專項科研基金(2000305):同步高表達PFP、GrB 基因的喉癌TIL抗腫瘤作用的研究。(2000)。

    二.文章
    (一)第一作者/通訊作者論文(SCI)
    1.Wang Z, Chen J, Hu J, Zhang H, Xu F, He W, Wang X, Li M, Lu W, Zeng G, Zhou P, Huang P, Chen S, Li W, Xia LP(共同通訊), Xia X. cGAS/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity. J Clin Invest. 2019 Aug 13;130. pii: 127471. doi: 10.1172/JCI127471.
    2.Guo G, Wang Y, Zhou Y, Quan Q, Zhang Y, Wang H, Zhang B, Xia L. Immune cell concentrations among the primary tumor microenvironment in colorectal cancer patients predicted by clinicopathologic characteristics and blood indexes. J Immunother Cancer. 2019 Jul 12;7(1):179. doi: 10.1186/s40425-019-0656-3.
    3.Guo GF, Wang YX, Zhang YJ, Chen XX, Lu JB, Wang HH, Jiang C, Qiu HQ, Xia LP. Predictive and prognostic implications of 4E-BP1, Beclin-1, and LC3 for cetuximab treatment combined with chemotherapy in advanced colorectal cancer with wild-type KRAS: Analysis from real-world data. World J Gastroenterol. 2019 Apr 21;25(15):1840-1853. doi: 10.3748/wjg.v25.i15.1840.
    4.Jiang C, Wang F, Guo G, Dong J, Liu S, He W, Zhang B, Xia L.Metastatic lymph node ratio as a prognostic indicator in patients with stage IV colon cancer undergoing resection.J Cancer. 2019 Jun 2;10(11):2534-2540.
    5.Kong P, Wang J, Song Z, Liu S, He W, Jiang C, Xie Q, Yang L, Xia X, Xia L.Circulating Lymphocytes, PD-L1 Expression on Tumor-infiltrating Lymphocytes, and Survival of Colorectal Cancer Patients with Different Mismatch Repair Gene Status.J Cancer. 2019 Apr 5;10(7):1745-1754
    6.Wu RY, Kong PF, Xia L(共一), Huang Y, Li ZL, Tang YY, Chen Y, Li X, Senthilkumar R, Zhang HL, Sun T, Xu XL, Yu Y, Mai J, Peng XD, Yang D, Zhou LH, Feng GK, Deng R, Zhu XF. Regorafenib promotes anti-tumor immunity via inhibiting PD-L1 and IDO1 expression in melanoma.Clin Cancer Res. 2019 Apr 2. pii: clincanres.2840.2018. doi: 10.1158/1078-0432.CCR-18-2840. [Epub ahead of print]
    7.Quan Q, Zhu M, Liu S, Chen P, He W, Huang Y, Rong Y, Qiu H, Zhang B, Xia L. Positive impact of the negative lymph node count on the survival rate of stage III colon cancer with pN1 and right-side disease. J Cancer. 2019 Jan 29;10(4):1052-1059.
    8.Liu S, Kong P, Wang X, Yang L, Jiang C, He W, Quan Q, Huang J, Xie Q, Xia X, Zhang B, Xia L.Tumor microenvironment classification based on T-cell infiltration and PD-L1 in patients with mismatch repair-proficient and -deficient colorectal cancer.Oncol Lett. 2019 Feb;17(2):2335-2343. 
    9.Yang L, Yang X, He W, Liu S, Jiang C, Xie K, Peng K, You Y, Zhang B, Xia L.Comparisons of metastatic patterns of colorectal cancer among patients by age group: a population-based study.Aging (Albany NY). 2018 Dec 28. doi: 10.18632/aging.101700. [Epub ahead of print]
    10.Yang L, He W, Xie Q, Liu S, Kong P, Jiang C, Zhang B, Xia L. Brain metastases in newly diagnosed colorectal cancer: a population-based study.Cancer Manag Res. 2018 Nov 15;10:5649-5658.
    11.Wang F, He W, Jiang C, Guo G, Ke B, Dai Q, Long J, Xia L. Prognostic value of inflammation-based scores in patients receiving radical resection for colorectal cancer.BMC Cancer. 2018 Nov 12;18(1):1102. doi: 10.1186/s12885-018-4842-3.
    12.Guo G, Chen X, He W, Wang H, Wang Y, Hu P, Rong Y, Fan L, Xia L.Establishment of inflammation biomarkers-based nomograms to predict prognosis of advanced colorectal cancer patients based on real world data.PLoS One. 2018 Dec 4;13(12):e0208547.
    13.Xie QK, Chen P, Hu WM, Sun P, He WZ, Jiang C, Kong PF, Liu SS, Chen HT, Yang YZ, Wang D, Yang L, Xia LP.The systemic immune-inflammation index is an independent predictor of survival for metastatic colorectal cancer and its association with the lymphocytic response to the tumor.J Transl Med. 2018 Oct 4;16(1):273. 
    14.Jiang C, Huang YH, Lu JB, Yang YZ, Rao HL, Zhang B, He WZ, Xia LP.Perivascular cell coverage of intratumoral vasculature is a predictor for bevacizumab efficacy in metastatic colorectal cancer.Cancer Manag Res. 2018 Sep 17;10:3589-3597.
    15.Yang L, Xiong Z, Xie QK, He W, Liu S, Kong P, Jiang C, Xia X, Xia L.Second primary colorectal cancer after the initial primary colorectal cancer.BMC Cancer. 2018 Sep 27;18(1):931. 
    16.He WZ, Hu WM, Kong PF, Yang L, Yang YZ, Xie QK, Jiang C, Yin CX, Qiu HJ, Zhang B, Zhang HZ, Xia LP.Systemic neutrophil lymphocyte ratio and mismatch repair status in colorectal cancer patients: correlation and prognostic value.J Cancer. 2018 Aug 6;9(17):3093-3100. 
    17.Yang L, Xiong Z, He W, Xie K, Liu S, Kong P, Jiang C, Guo G, Xia L. Proximal shift of colorectal cancer with increasing age in different ethnicities.Cancer Manag Res. 2018 Aug 15;10:2663-2673.
    18.He WZ, Yang QX, Xie JY, Kong PF, Hu WM, Yang L, Yang YZ, Xie QK, Jiang C, Yin CX, Guo GF, Qiu HJ, Zhang B, Xia LP.Association of low skeletal muscle index with increased systematic inflammatory responses and interferon γ-induced protein 10 levels in patients with colon cancer.Cancer Manag Res. 2018 Aug 7;10:2499-2507
    19.Liu SS, Yang YZ, Jiang C, Quan Q, Xie QK, Wang XP, He WZ, Rong YM, Chen P, Yang Q, Yang L, Zhang B, Xia XJ, Kong PF, Xia LP.Comparison of immunological characteristics between paired mismatch repair-proficient and -deficient colorectal cancer patients.J Transl Med. 2018 Jul 13;16(1):195. doi: 10.1186/s12967-018-1570-z.
    20.He WZ, Xie QK, Hu WM, Kong PF, Yang L, Yang YZ, Jiang C, Yin CX, Qiu HJ, Zhang HZ, Zhang B, Xia LP.An increased number of negative lymph nodes is associated with a higher immune response and longer survival in colon cancer patients.Cancer Manag Res. 2018 Jun 18;10:1597-1604.
    21.Xie QK, He WZ, Hu WM, Yang L, Jiang C, Kong PF, Yang YZ, Yang Q, Zhang HZ, Zhang B, Xia LP.Tumor-infiltrating lymphocyte as a prognostic biomarker in stage IV colorectal cancer should take into account the metastatic status and operation modality.Cancer Manag Res. 2018 May 30;10:1365-1375.
    22.Yang L, Xiong Z, Xie Q, He W, Liu S, Kong P, Jiang C, Guo G, Xia L. Prognostic value of total number of lymph nodes retrieved differs between left-sided colon cancer and right-sided colon cancer in stage III patients with colon cancer. BMC Cancer. 2018 May 11;18(1):558. doi: 10.1186/s12885-018-4431-5.
    23.Jiang C, Cai X, Zhang H, Xia X, Zhang B, Xia L.Activity and Immune Correlates of a Programmed Death-1 Blockade Antibody in the treatment of Refractory Solid Tumors.J Cancer. 2018 Jan 1;9(1):205-212.
    24.Wang H, Peng R, Chen X, Jia R, Huang C, Huang Y, Xia L(共同通訊), Guo G. Effect of HK2, PKM2 and LDHA on Cetuximab efficacy in metastatic colorectal cancer. Oncol Lett. 2018 Apr;15(4):5553-5560.
    25.Yang L, He W, Kong P, Jiang C, Yang Q, Xie Q, Xia LP. Clinical baseline and prognostic difference of platelet lymphocyte ratio (PLR) in right-sided and let-sided colon cancers. BMC Cancer. 2017 Dec 20;17(1):873. doi: 10.1186/s12885-017-3862-8.
    26.Yang L, He W, Yang Q, Kong P, Xie Q, Jiang C, Zhang B, Xia LP.Combination of primary tumor location and mismatch repair status guides adjuvant chemotherapy in stage II colon cancer.Oncotarget. 2017 Oct 12;8(58):99136-99149. 
    27.Kong P, Wu R, Lan Y, He W, Yang C, Yin C, Yang Q, Jiang C, Xu D, Xia L.Association between Mismatch-repair Genetic variation and the Risk of Multiple Primary Cancers: A Meta-Analysis.J Cancer. 2017 Sep 16;8(16):3296-3308.
    28.Yang L, Xia L(共同第一), Wang Y, He S, Chen H, Liang S, Peng P, Hong S, Chen Y.Development and external validation of nomograms to predict the risk of skeletal metastasis at the time of diagnosis and skeletal metastasis-free survival in nasopharyngeal carcinoma.BMC Cancer. 2017 Sep 6;17(1):628. 
    29.Jiang C, Liu S, He W, Zhang B, Xia L. The Prognostic and Predictive Value of Carbohydrate Antigen 19-9 in Metastatic Colorectal Cancer Patients with First Line Bevacizumab Containing Chemotherapy. J Cancer. 2017 May 12;8(8):1410-1416.
    30.Quan Q, Huang Y, Chen Q, Qiu H, Hu Q, Rong Y, Li T, Xia L, Zhang B.Impact of Serum Apolipoprotein A-I on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer: a Propensity Score-Matched Analysis. Transl Oncol. 2017 Apr;10(2):288-294. doi: 10.1016/j.tranon.2017.01.006. Epub 2017 Mar 2.
    31.He WZ, Liao FX, Jiang C, Kong PF, Yin CX, Yang Q, Qiu HJ, Zhang B, Xia LP.Primary Tumor Location as a Predictive Factor for First-line Bevacizumab Effectiveness in Metastatic Colorectal Cancer Patients. J Cancer. 2017 Feb 10;8(3):388-394.
    32.Kong P, Zhu X, Geng Q, Xia L(共同第一), Sun X, Chen Y, Li W, Zhou Z, Zhan Y, Xu D.The microRNA-423-3p-Bim Axis Promotes Cancer Progression and Activates Oncogenic Autophagy in Gastric Cancer.Mol Ther. 2017 Feb 18. pii: S1525-0016(17)30020-5. doi: 10.1016/j.ymthe.2017.01.013. [Epub ahead of print]
    33.Kong P, Wu R, Liu X, Liu J, Chen S, Ye M, Yang C, Song Z, He W, Yin C, Yang Q, Jiang C, Liao F, Peng R, Zhou Z, Xu D, Xia L.The Effects of Anti-inflammatory Drug Treatment in Gastric Cancer Prevention: an Update of a Meta-analysis.J Cancer. 2016;7(15):2247-2257.
    34.Yin C, Ma G, Rong Y, Kong P, Yang Q, Jiang C, Liao F, Zhang B, He W, Xia L.The Efficacy of Bevacizumab in Different Line Chemotherapy for Chinese Patients with Metastatic Colorectal Cancer. J Cancer. 2016 Sep 13;7(13):1901-1906.
    35.Kong P, Wu R, Yang C, Geng Q, Liu J, Chen S, Liu X, Ye M, He W, Yang Q, Xia L, Xu D. Prognostic Impact of the Signet Ring Cell Type in Node-Negative Gastric Cancer. Sci Rep. 2016;6:26313. doi: 10.1038/srep26313.
    36.Yang L, Xia L, Wang Y, Hong S, Chen H, Liang S, Peng P, Chen Y. Low Prognostic Nutritional Index (PNI) Predicts Unfavorable Distant Metastasis-Free Survival in Nasopharyngeal Carcinoma: A Propensity Score-Matched Analysis. PLoS One. 2016 Jul 11;11(7):e0158853. doi: 10.1371/journal.pone.0158853. eCollection 2016.
    37.He WZ, Rong YM, Jiang C, Liao FX, Yin CX, Guo GF, Qiu HJ, Zhang B, Xia LP. Palliative primary tumor resection provides survival benefits for the patients with metastatic colorectal cancer and low circulating levels of dehydrogenase and carcinoembryonic antigen.Chin J Cancer. 2016;35(1):58. doi: 10.1186/s40880-016-0120-4.
    38.Yang Q, Liao F, Huang Y, Jiang C, Liu S, He W, Kong P, Zhang B, Xia L. Longterm effects of palliative local treatment of incurable metastatic lesions in colorectal cancer patients. Oncotarget. 2016 Apr 12;7(15):21034-45.
    39.Jiang C, Hu WM, Liao FX, Yang Q, Chen P, Rong YM, Guo GF, Yin CX, Zhang B, He WZ, Xia LP. Elevated preoperative neutrophil-to-lymphocyte ratio is associated with poor prognosis in gastrointestinal stromal tumor patients. Onco Targets Ther. 2016;9:877-83. 
    40.Liao F, He W, Jiang C, Yin C, Guo G, Chen X, Qiu H, Rong Y, Zhang B, Xu D, Xia L. A high LDL-C to HDL-C ratio predicts poor prognosis for initially metastatic colorectal cancer patients with elevations in LDL-C.Onco Targets Ther. 2015;8:3135-3142.
    41.Yang Q, Yin C, Liao F, Huang Y, He W, Jiang C, Guo G, Zhang B, Xia L.Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer.Onco Targets Ther. 2015;8:2407-13. 
    42.Chen ZY, He WZ, Peng LX, Jia WH, Guo RP, Xia LP(共同通訊), Qian CN.A prognostic classifier consisting of 17 circulating cytokines is a novel predictor of overall survival for metastatic colorectal cancer patients.Int J Cancer. 2015 Feb 1;136(3):584-92. 
    43.He WZ, Yin CX, Jiang C, Guo GF, Rong RM, Qiu HJ, Chen XX, Zhang B, Xia LP. Prognostic Model Built on Blood-based Biomarkers in Patients with Metastatic Colorectal Cancer. Asian Pac J Cancer Prev. 2014; ;15(17):7327-31.
    44.Yin C, Jiang C, Liao F, Rong Y, Cai X, Guo G, Qiu H, Chen X, Zhang B, He W, Xia L. Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer. Onco Targets Ther. 2014;7:1415-22.
    45.Jiang C, Liao FX, Rong RM, Yang Q, Yin CX, He WZ, Cai XY, Guo GF, Qiu HJ Chen XX, Zhang B, Xia LP. Efficacy of Taxane-Based Regimens in a First-line Setting for Recurrent and/or Metastatic Chinese Patients with Esophageal Cancer. Asian Pac J Cancer Prev. 2014;15(13):5493-8.
    46.He WZ, Guo GF, Yin CX, Jiang C, Wang F, Qiu HJ, Chen XX, Rong RM, Zhang B, Xia LP. γ-Glutamyl transpeptidase level is a novel adverse prognostic indicator in human metastatic colorectal cancer. Colorectal Dis. 2013 Aug;15(8):e443-52. 
    47.He W, Yin C, Guo G, Jiang C, Wang F, Qiu H, Chen X, Rong R, Zhang B, Xia L. Initial Neutrophil Lymphocyte Ratio Is Superior To Platelet Lymphocyte Ratio As An Adverse Prognostic and Predictive Factor In Metastatic Colorectal Cancer. Medical Oncology. 2013 Mar;30(1):439.
    48.Wang F, He W, Qiu H, Wang X, Guo G, Chen X, Rong Y, Zhou F, Yin C, Yuan Z, Xia L. Lymph Node Ratio and pN Staging Show Different Superiority As Prognostic Predictors Depending on the Number of Lymph Nodes Dissected in Chinese Patients with Luminal A Breast Cancer. Clin Breast Cancer. 2012 Dec;12(6):404-11.
    49.Wang F, Guo GF, Qiu HJ, He WZ, Zhou FF, Chen XX, Hu PL, Zhang B, Yin CX, Zhang L, Xia LP.Initial Progression-Free Survival after Non-First Line TKIs Therapy Potentially Guides Immediate Treatment after Its Failure in Advanced Non-Small Cell Lung Cancer.Cancer Biol Med. 2012 Mar;9(1):38-43.
    50.Guo GF, Jiang WQ, Zhang B, Cai YC, Xu RH, Wang F, Chen XX, Xia LP. Autophagy-related proteins Beclin-1 and LC3 predict cetuximab efficacy in advanced colorectal cancer. World J Gastroenterol. 2011; 17(43): 4839-4846.
    51.Zhou FF, Yan M, Guo GF, Wang F, Qiu HJ, Zheng FM, Zhang Y, Liu Q, Zhu XF, Xia LP*.Knockdown of eIF4E suppresses cell growth and migration, enhances chemosensitivity correlates with increase of Bax/Bcl-2 ratio in triple-negative breast cancer cells. Med Oncol. 2011 Dec;28(4):1302-7.
    52.Xia LP, Qiu HJ, Chen XX, Hu PL, Guo GF, Wang F, Zhou FF, He WZ, Zhang B, Zhang L. Short-term outcomes of cetuximab combined with standard chemotherapy as first line setting for Chinese patients with Non-small cell lung cancer: a report of 12 cases. Med Oncol. 2011 Dec;28 Suppl 1:570-6.
    53.Guo GF, Cai YC, Zhang B, Xu RH, Qiu HJ, Xia LP, Jiang WQ, Hu PL, Chen XX, Zhou FF, Wang F.Overexpression of SGLT1 and EGFR in colorectal cancer showing a correlation with the prognosis. Med Oncol. 2011 Dec;28 Suppl 1:197-203.(共同通訊)
    54.Zhou FF, Xia LP, Guo GF, Wang X, Yuan ZY, Zhang B, Wang F. Changes in Therapeutic Strategies in Chinese Male Patients with Breast Cancer: 40 Years of Experience in a Single Institute. Breast. 2010;19(6):450-5.
    55.Xia LP, Zhou FF, Guo GF, Wang F, Wang X, Yuan ZY, Zhang B. Chinese Female Breast Cancer Patients Show A Better Overall Survival Than Their Male Counterparts. Chinese Medicine Journal. 2010;123(17):2347-2352.
    56.Zhang B, He WZ, Zhou FF, Guo GF, Jiang C, Yin CX, Chen XX, Qiu HJ, Rong RM, Xia LP. A Potential Administration-time Dependent Effect of Bevacizumab in Improving Overall Survival and Increasing Metastasis in Metastatic Colorectal Cancer. Chemotherapy. 2013, 2:108. doi:10.4172/2167-7700.1000108

    第一作者/通訊作者論文(非SCI)
    57.Yin CX, Jiang C, Liao FX, Rong RM, He WZ,Cai XY, Guo GF, Qiu HJ Chen XX, Zhang B, Xia LP.The efficacy of bevacizumab in Chinese patients with metastatic colorectal cancer and its effect in different line setting. Chinese-German Journal of Clinical Oncology. 2014;13(4): 169-173.
    58.Qiu HJ, He WZ, Yin CX, Guo GF, Wang F, Zhou FF, Jiang C, Xia LP. The efficacy and its related issues of combination of bevacizumab and taxanes-based regimens in Chinese patients with metastatic breast cancer. Chinese-German Journal of Clinical Oncology. 2012;11(10): 585-591.
    59.Wang F, Guo GF, Qiu HJ, He WZ, Zhou FF , Chen XX, Hu PL, Zhang B, Yin CX, Zhang L, Xia LP. Initial Progression-Free Survival after Non-First Line TKIs Therapy Potentially Guides Immediate Treatment after Its Failure in Advanced Non-Small Cell Lung Cancer. Cancer Biology & Medicine. 2012;9(1):38-43.
    60.Wang F, Guo GF, Qiu HJ, Chen XX, Hui PL, Zhou FF, He WZ, Zhang B, Xia LP. Pemetrexed Monotherapy and Pemetrexed Plus Platinum Combination Therapy as Non-First-Line Treatments for Advanced Non-Small Cell Lung Cancer. Clin Oncol Cancer Res. 2011; 8(4): 235–241
    61.Qiu HJ, He WZ, Chen XX, Guo GF, Wang F, Zhou FF, Xia LP. The pooled analysis of efficacy and safety profiles of bevacizumab in Chinese cancer patients. Chinese-German Journal of Clinical Oncology.2011;10(11): 621-625.
    62.Zhou FF,  Huang R, Jiang J, Wang F,  He WZ, Guo GF, Xia LP. A meta-analysis based on case-control studies shows the similar prognosis between male and female patients with breast cancer. Chinese-German Journal of Clinical Oncology.2011;10(6): 311-316.
    63.Qiu HJ, Wang F, Guo GF, Zhou FF, He WZ, Xia LP. Non-platinum doublets versus single agents in non-small cell lung cancer (NSCLC) patients with elderly age and/or poor performance status: a meta-analysis. Chinese-German Journal of Clinical Oncology. 2011;10(3): 134-139.
    64.Wang F, Xia LP, Guo GF, Qiu HJ, Zhou FF, He WZ. The Pooled Analysis of Single Gemcitabine For Non-Small Cell Lung Cancer (NSCLC) Patients With Elderly Age. Chinese-German Journal of Clinical Oncology.2010;9(12):683-687.
    65.丘惠娟,夏良平,汪芳,郭桂芳,周菲菲,張蓓,張力.Cetuximab聯合一線和非一線化療方案治療16 例非小細胞肺癌近期療效及其療效差異.南方醫科大學學報.2010;30(11):2423-2426.
    66.Wang F, Xia LP, Guo GF, et al. Short-term outcomes of cetuximab combined with standard chemotherapy as non-first line setting for patients with Non-small cell lung cancer: a report of 6 cases. Chinese-German Journal of Clinical Oncology.2010;9(9):502-506. 
    67.Xia LP, Yuan ZY, Wang X, et al. Characteristics of Chinese Male Patients with Breast Cancer: Summary of the Published Papers. Chinese-German Journal of Clinical Oncology.2010;9(6):311-315.
    68.周菲菲,夏良平,王曦,郭桂芳,戎煜明,丘惠娟,張蓓.72例男性乳腺癌患者臨床病理特征和預后分析.中國腫瘤臨床. 2010;37(22):1296-1299.
    69.Xia LP, Rong YM, Guo GF, et al. The summary of efficacy of cetuximab combination with chemotherapy in NSCLC first-line setting: based on publication. Chinese-German Journal of Clinical Oncology.2010;9(3):137-141.
    70.丘惠娟,夏良平,徐瑞華,張蓓,郭桂芳,戎煜明,周菲菲,汪芳.含Cetuximab方案治療10例胃癌和食管癌的近期療效分析.腫瘤學雜志.2010;16(4):294-297.
    71.周菲菲,夏良平,王曦,郭桂芳,戎煜明,丘惠娟,張蓓.影響男性乳腺癌預后的多因素分析—單中心72例臨床資料總結.癌癥.2010;29(2):196-201.
    72.夏良平,張力,張蓓,郭桂芳,丘惠娟,戎煜明,汪桃利,周菲菲.Cetuximab聯合化療治療非小細胞肺癌近期療效分析—附2例報告及文獻綜述.腫瘤學雜志.2010;16(2):133-138.
    73.Xia LP, Guo GF,Zhang B, et al. Short-term Efficacy of Cetuximab-contained Regimen on Patients with Advanced Gastrointestinal (Noncolorectal) Cancer: Experiences of 16 Patients in Single Institute. Chinese-German Journal of Clinical Oncology.2009; 8(11):669-674.
    74.Xia LP, Guo GF,Qiu HJ, et al. Efficacy and safety profiles of cetuximab in Chinese patients with colorectal cancer. Chinese-German Journal of Clinical Oncology.2009;8(9):526-530.
    75.夏良平, 張蓓, 郭桂芳, 等. 鼻咽癌放療后殘留和復發頸淋巴結的分布規律. 中山大學學報(醫學科學版).2009;30(supple 4):199-202.
    76.夏良平,張蓓, 劉茂珍, 等.Cetuximab聯合放療或化療治療11例頭頸惡性腫瘤近期療效分析.癌癥.2009.28(9):977-982.
    77.Xia LP, Zeng ZY, Guo ZM, Guo GF, Zhang B, Qiu HJ, Zhou FF. Neck dissection for recurrent and persistent lymph nodes of nasopharyngeal carcinoma after radiotherapy: effect and choice. Chinese-German Journal of Clinical Oncology.2009;8(2):81-85.
    78.夏良平,張蓓,丘惠娟,等.鼻咽癌放療后頸淋巴結殘留與復發的療效差異.中山大學學報(醫學科學版).2008;29(supple 3):41-44.
    79.夏良平, 李秀英, 張詮, 等. 人穿孔素擴增與表達分析. 腫瘤學雜志,2006;12(3):188-190.
    80.華輝, 陳靜靜, 夏良平, 等. 腫瘤浸潤性T淋巴細胞ζ鏈異常表達在舌癌預后中的價值. 中國腫瘤. 2009,18(40):304-307.
    81.夏良平, 曾宗淵, 陳直華, 等. 鼻咽癌放療后頸淋巴結復發和殘留的外科治療. 中華耳鼻咽喉科雜志, 2005,40(2):95-99.
    82.Xia LP, Zeng ZY, Guo ZM, et al . The Value Of Pathological and Molecular Margins To Direct The Postoperative Treatments Of Laryngeal Carcinoma. The Chinese-German Journal of Clinical Ocology. 2005,4(1):56-60.
    83.夏良平,曾宗淵,許光普,等. 喉鱗癌原發灶和切緣中P53蛋白表達對術后治療的指導價值.中華腫瘤雜志, 2003,25(6):558-561.
    84.夏良平,許光普,曾宗淵,等. 喉鱗癌手術切緣eIF4E蛋白表達與預后的關系.中華耳鼻咽喉科雜志, 2003,38(2):139-142.
    85.夏良平, 陳直華,陳忠平,等. 顱面聯合進路切除顱底惡性腫瘤16例臨床總結. 中國神經腫瘤雜志,2004,2(1):62-66.
    86.夏良平, 曾宗淵, 郭朱明, 等.喉鱗癌原發灶及無瘤手術切緣組織p53蛋白表達及其與預后的研究. 癌癥.2003; 22(1):77-82.
    87.夏良平,曾宗淵,許光普,等.喉鱗癌病理學陰性切緣中eIF4E和P53蛋白檢測及其意義.腫瘤, 2003,23(6):505-507.
    88.夏良平,曾宗淵,郭朱明,等. 喉癌術后頸淋巴結復發的多因素分析. 中華臨床醫學實踐雜志.2003;2(12):1057-1060.
    89.夏良平,曾宗淵,許光普,等. 喉鱗癌原發灶中eIF4E和P53蛋白表達特征及意義. 臨床耳鼻咽喉科雜志.2003,17(增刊):35-37.
    90.夏良平,曾宗淵,陳福進,等.保留喉功能的治療方法在喉癌T3病例中的應用探討. 癌癥, 2001,20(5):511-514.
    91.夏良平, 李添應, 陳明遠,等. 鼻息肉患者鼻息肉組織及鼻分泌物中白細胞介素-5的測定.耳鼻咽喉-頭頸外科, 2001, 8(1):38-41.
    92.夏良平, 曾宗淵, 魏茂文, 等. 影響喉癌生存率諸因素的單因素和多因素分析. 中國腫瘤.2002; 11(11):655-657. 
    93.夏良平, 曾宗淵, 曾敬,等.eIF4E及其ser-209磷酸化蛋白在喉鱗癌中表達特征及意義. 中國腫瘤2004,13(3):171-173.
    94.夏 良 平, 曾 宗 淵, 郭朱明,等. 喉癌三種不同頸淋巴結轉移狀態者生存率分析. 腫瘤. 2004,24(4):388-391.
    95.夏良平,曾宗淵,陳直華,等.部分喉切除術中影響切緣結果的因素分析.腫瘤學雜志. 2004,10(4):220-222.

    (二)非第一作者論文
    96.Chen P, Zhang B, Guo GF, Xia LP, Qiu HJ. Efficacy comparison between hepatic arterial infusion chemotherapy plus systemic chemotherapy used as first-line and non-first-line treatments for the patients of colorectal cancers with unresectable hepatic metastases. Chinese-German Journal of Clinical Oncology.2014.13(5):229-234.
    97.Sun T, Li D, Wang L, Xia L, Ma J, Guan Z, Feng G, Zhu X. c-Jun NH2-terminal kinase activation is essential for up-regulation of LC3 during ceramide-induced autophagy in human nasopharyngeal carcinoma cells. J Transl Med. 2011 Sep 26;9:161.
    98.Deng R, Tang J, Xia LP, Li DD, Zhou WJ, Wang LL, Feng GK, Zeng YX, Gao YH, Zhu XF. ExcisaninA, a diterpenoid compound purified from Isodon MacrocalyxinD, induces tumor cells apoptosis and suppresses tumor growth through inhibition of PKB/AKT kinase activity and blockade of its signal pathway.Mol Cancer Ther. 2009;8(4):873-882.(IF=5.003)
    99.Deng R, Tang J, Ma JG, Chen SP, Xia LP, Zhou WJ, Li DD, Feng GK, Zeng YX, Zhu XF.PKB/Akt promotes DSB repair in cancer cells through upregulating Mre11 expression following ionizing radiation.Oncogene.
    Oncogene. 2011 Feb 24;30(8):944-55.
    100.Yao JE, Yan M, Guan Z, Pan CB, Xia LP, Li CX, Wang LH, Long ZJ, Zhao Y, Li MW, Zheng FM, Xu J, Lin DJ, Liu Q.Aurora-A down-regulates IkappaBalpha via Akt activation and interacts with insulin-like growth factor-1 induced phosphatidylinositol 3-kinase pathway for cancer cell survival.Mol Cancer. 2009 Nov 5;8:95. (IF=5.362)
    101.Wan XB, Long ZJ, Yan M, Xu J, Xia LP, Liu L, Zhao Y, Huang XF, Wang XR, Zhu XF, Hong MH, Liu Q.Inhibition of Aurora-A suppresses epithelial-mesenchymal transition and invasion by downregulating MAPK in nasopharyngeal carcinoma cells.Carcinogenesis. 2008;29(10):1930-1937. (IF=4.93)
    102.郭桂芳,夏良平,徐瑞華,陳徐賢,汪 芳,何文卓,姜文奇.西妥昔單抗聯合化療治療晚期結直腸癌的生存分析及KRAS對療效的影響. 中山大學學報醫學科學版. 2011;32(5): 637-643.
    103.郭桂芳,夏良平,丘惠娟,等.西妥昔單抗聯合化療治療102例K-ras狀態不明晚期結直腸癌的療效.中華腫瘤雜志.2010;32(10):777-781.
    104.徐大志, 夏良平, 林桐榆, 等. 磷酸化的哺乳動物雷帕霉素靶蛋白在胃癌組織中的表達.中山大學學報醫學科學版. 2009;30(3): 304-307. 
    105.李秀英, 夏良平, 賴延東.人PFP、GrB共表達誘導喉癌Hep-2細胞凋亡的研究.免疫學雜志,2009;25(2):150-157.
    106.李秀英,夏良平, 賴延東.PFP、GrB的共表達殺傷人喉癌Hep-2細胞的體外研究.現代免疫學. 2008; 28(3):224-228. 
    107.李秀英, 夏良平, 賴延東. PFP、GrB真核共表達載體的構建及表達分析.中國免疫學雜志,2008,24(6):492-495.
    108.陳明遠, 夏良平, 陳直華,等.植人式靜脈輸液港不同植人術式在惡性腫瘤患者中的應用. 中山大學學報(醫學科學版).2007;28(3S):145-147.
    109.葉石敦, 夏良平, 賴延東. 重組人顆粒酶B對胃癌細胞增殖的影響.山東醫藥,2006;46(6):15-16.
    110.郭桂芳,夏良平,張蓓,姜文奇,丘惠娟,劉茂珍,胡丕麗,陳徐賢,周菲菲.西妥昔單抗聯合化療治療53例晚期結直腸癌的療效. 癌癥.2009;28(12):1317-1323.
    111.曾宗淵,夏良平,陳福進,等.術中留取切緣標本對早期喉癌患者術后治療的指導價值. 中華耳鼻咽喉科雜志, 2001,36(4):250-253.
    112.李添應, 夏良平, 陳明遠,等. 白細胞介素-5及嗜酸性粒細胞在鼻息肉中的相關性研究. 臨床耳鼻咽喉科雜志, 2000, 14(11):488-490.
    113.李添應, 夏良平, 孟慶翔, 等.nm23-H1基因在鼻腔鼻竇內翻性乳頭狀瘤及其癌變組織中的表達. 臨床耳鼻咽喉科學雜志. 2004,18(2):86-87.
    114.曾宗淵,夏良平,郭朱明,等.喉癌治療方法的選擇和失敗原因分析. 癌癥,2001, 20(11):1012-1015. 
    115.李秀英, 賴延東, 夏良平, 等. 人顆粒酶B基因的克隆、蛋白純化及表達分析. 現代免疫學,.2004,24(6):486-489.
    116.李秀英, 賴延東, 夏良平, 等.人穿孔素基因真核表達載體的構建與表達分析. 免疫學雜志, 2005,21(6):546
    117.李添應, 邱前輝, 夏良平.功能性內窺鏡鼻竇手術對嗅覺及嗅粘膜上皮形態的影響. 中山醫科大學學報, 2000,21(6):473-477
    118.許光普, 曾宗淵, 夏良平, 等. 部分喉切除術切緣病理學檢查對術后治療及預后估計的意義. 癌癥,2002,21(2):200-203.
    119.郭朱明, 曾宗淵, 夏良平,等.口底鱗狀細胞癌轉移性頸淋巴結分布特點及處理的探討. 癌
    120.楊安奎, 陳福進,曾宗淵, 夏良平. 全喉切除術前喉裂開探查對病人預后的影響. 中國腫瘤, 2001,10(9):550-552.
    121.郭朱明,曾宗淵,夏良平,等. 微波固化在口腔癌中的臨床應用—附96例臨床總結. 癌癥.2003; 22(1):71-76.
    122.黃湛, 曾宗淵, 官梅, 夏良平. iNOS和bFGF在聲門上喉鱗癌中的表達及意義. 癌癥.2002; 21(9 ): 961-964.
    123.黃湛, 曾宗淵, 彭漢偉, 夏良平,等.聲門上喉鱗癌組織中誘導型一氧化氮合酶和堿性成纖維細胞生長因子表達與預后的關系.癌癥. 2003,22(9):978-981.
    124.張詮, 曾宗淵, …夏良平.等.微波固化治療口腔癌的療效分析. 癌癥, 2001, 20(10):1100-1103.
    125.郭朱明, 曾宗淵, 夏良平,等.口底鱗狀細胞癌轉移性頸淋巴結分布特點及處理的探討. 癌癥.2002; 21(9):979-982.
    126.曾宗淵,張 詮,…夏良平.微波固化與外科手術治療口底癌的療效比較. 中華耳鼻咽喉科雜志, 2002,37(2):90-94.
    127.許光普, 曾宗淵, 陳福進,… 夏良平.等. 新輔助化療治療晚期喉癌及喉咽癌的近期療效評定. 臨床腫瘤學雜志2002;7(6):413-415.

    (三)綜述及病例報道
    128.江暢, 夏良平. 腫瘤干細胞糖代謝的研究進展. 腫瘤學雜志,2014;20(3): 947-950.
    129.陳平, 夏良平, 張蓓. 癌細胞中葡萄糖代謝與轉運特點. 腫瘤學雜志,2014;20(3):244-247.
    130.尹晨希,周菲菲, 夏良平. 惡性腫瘤患者血清中PKM2水平的診斷和預后預測價值。腫瘤學雜志,2013;19(7):565-569.
    131.Xia LP, Wu PH, Xia JC, Zhang B, Guan ZZ, Wan DS, Guo GF, Zeng YX. One patient with metastastic colorectal cancer successfully treated by combination of targeted agents after failure of chemotherapy.Chin J Cancer. 2010 Dec;29(12):1023-8.
    132.夏良平,郭桂芳.含西妥昔單抗方案治療胃癌和食管癌的近期療效.國際腫瘤學雜志,2010;37(3):217-219.
    133.夏良平,周菲菲,楊名添,等. Aurora-A在乳腺癌致瘤機制和預后方面的研究進展.癌癥.2009;28(7):668-672.
    134.夏良平,周菲菲,劉強. Aurora-A激酶抑制劑的抗腫瘤作用.臨床腫瘤學雜志.2009;10(10):941-945.
    135.夏良平,周菲菲,楊名添,謝小明.乳腺癌中基因標簽研究的共性問題. 國際腫瘤學雜志. 2009;36(4):280-282.
    136.夏良平,周菲菲,曾宗淵. Cetuximab聯合放療和/或化療治療頭頸癌研究進展.中華腫瘤防治雜志.2009;16(20 supple):74-77.
    137.周菲菲,夏良平,王曦.真核起始因子4E在乳腺癌中的研究進展.國際腫瘤學雜志. 2009;36(11):850-852.(通訊作者)
    138.汪芳,夏良平.Cetuximab在晚期非小細胞肺癌一線治療中的研究進展. 腫瘤學雜志. 2011;17(9):649-652. (通訊作者)
    139.郭桂芳夏良平,姜文奇.自噬及其與結直腸癌的發生和治療. 國際腫瘤學雜志. 2010;37(10):774-777.
    140.夏良平.喉癌誘導化療的臨床研究進展. 耳鼻咽喉-頭頸外科, 2001,8(2):125-128.
    141.夏良平. 喉癌外科切緣的臨床與分子生物學研究. 國外醫學.腫瘤學分冊,2001,28(增刊):89-91.
    142.夏良平. eIF4E作用和調節機制. 國外醫學.分子生物學分冊, 2001,23(5):280-282.
    143.夏良平. 聲門上型喉癌N0患者頸淋巴結轉移及處理. 臨床耳鼻咽喉科雜志, 2001,15(12):569-571
    144.夏良平.喉癌根治性放療失敗后挽救性手術治療. 國外醫學.耳鼻咽喉科分冊,2002,26(1):24-28.
    145.曾宗淵, 夏良平.鼻咽癌研究進展.腫瘤學雜志.2003,9(1):36-39.
    146.夏良平.白介素-5與嗜酸性粒細胞凋亡. 國外醫學、生理、病理科學與臨床分冊,  1999, 19(4):301-303.

    社會任職
    1.廣東省健康管理學會腫瘤防治專業委員會,主任委員
    2.廣東省健康管理學會干細胞與再生醫學專委會,副主任委員
    3.廣東省抗癌協會靶向與個體化治療專業委員會,常委
    4.廣東省抗癌協會化療專業委員會,委員


    更新日期:2019年9月25日
訪客通道
員工通道
關注腫瘤醫院
留言建議 ×
沙巴体育下载